Ibuprofen


Description

Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[

Read more

Pharmacology

Indication

Ibuprofen is the most commonly used and prescribed NSAID. It is very common over the counter medicat... Read more

Pharmacodynamic

Ibuprofen has multiple actions in different inflammatory pathways involved in acute and chronic infl... Read more

Mechanism of action

The exact mechanism of action of ibuprofen is unknown. However, ibuprofen is considered an NSAID and... Read more

Absorption

It is very well absorbed orally and the peak serum concentration can be attained in 1 to 2 hours aft... Read more

Protein binding

Ibuprofen dosage is more than 99% bound to plasma proteins and site II of purified albumin, binding... Read more

Volume of distribution

The apparent volume of distribution of ibuprofen is of 0.1 L/kg.[ Read more

Clearance

The clearance rate ranges between 3-13 L/h depending on the route of administration, enantiomer type... Read more

Half life

The serum half-life of ibuprofen is 1.2-2 hours.[ Read more

Route of elimination

Ibuprofen is rapidly metabolized and eliminated in the urine thus, this via accounts for more than 9... Read more

Toxicity

The symptoms of overdose are presented in individuals that consumed more than 99 mg/kg. Most common... Read more


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Epigastric Pain US
  • Kind: experimental
    • Percent: 3-9%
  • Clinical Trial
    Heartburn US
  • Kind: experimental
    • Percent: 3-9%
  • Clinical Trial
    Dizziness US
  • Kind: experimental
    • Percent: 3-9%
  • Clinical Trial
    Rash US
  • Kind: experimental
    • Percent: 3-9%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: 3-9%
  • Clinical Trial
    Abdominal Cramps US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Constipation US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Fullness of GI tract US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Abdominal Pain US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Abdominal distress US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Diarrhea US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Indigestion US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Nausea and vomiting US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Edema US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Decreased appetite US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Fluid retention US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Nervousness US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Headache US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Tinnitus US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Pruritus US
  • Kind: experimental
    • Percent: 1-3%
  • Clinical Trial
    Gastric ulcer with bleeding or perforation US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Scotomata US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Diminished vision US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Blurred vision US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Amblyopia US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Hearing Loss US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Alopecia US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Stevens-Johnson Syndrome US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Erythema multiforme US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Eosinophilia US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Thrombocytopenic Purpura US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Thrombocytopenia US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Hemolytic Anemia US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Aplastic Anemia US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Agranulocytosis US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Neutropenia US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Changes in color vision US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Abnormal Liver Function Tests US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Pancreatitis US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Hepatitis US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Jaundice US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Melena US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Gastritis US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Duodenal ulcer with bleeding or perforation US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Gastrointestinal Hemorrhage US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Vesiculobullous eruptions US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Urticaria US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Somnolence US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Aseptic meningitis with fever and coma US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Confusion US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial

    Contraindications

    • Route:
      • Oral
    • Regions: US
    • With Therapies:
        • Name: Coronary artery bypass graft (CABG) surgery
        • Drugbank Id: DBCOND0107829
    • Hypersensitivity:
      • aspirin
      • Anti-Inflammatory Agents, Non-Steroidal
    • Regions: US

    Food Interactions

    • Avoid alcohol
    • Food delays the time to reach peak plasma concentrations by 30-60 minutes and reduces peak plasma concentrations by 30-50%. Extent of absorption is unaffected.
    • Take with food to reduce gastric irritation.

    Interactions

    Type in a drug name to check for interaction with Ibuprofen

    The metabolism of (R)-warfarin can be decreased when combined with Ibuprofen.
    The metabolism of (S)-Warfarin can be decreased when combined with Ibuprofen.
    The risk or severity of hypertension can be increased when Ibuprofen is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
    The risk or severity of hypertension can be increased when Ibuprofen is combined with 1-benzylimidazole.
    The risk or severity of hypertension can be increased when Ibuprofen is combined with 2,5-Dimethoxy-4-ethylamphetamine.
    The risk or severity of hypertension can be increased when Ibuprofen is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
    The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Ibuprofen.
    The risk or severity of hypertension can be increased when Ibuprofen is combined with 4-Bromo-2,5-dimethoxyamphetamine.
    The metabolism of 4-hydroxycoumarin can be decreased when combined with Ibuprofen.
    The risk or severity of hypertension can be increased when Ibuprofen is combined with 4-Methoxyamphetamine.
    The metabolism of 5-androstenedione can be decreased when combined with Ibuprofen.
    The risk or severity of hypertension can be increased when Ibuprofen is combined with 5-methoxy-N,N-dimethyltryptamine.
    The metabolism of Ibuprofen can be decreased when combined with 6-Deoxyerythronolide B.
    The metabolism of 6-O-benzylguanine can be decreased when combined with Ibuprofen.
    The metabolism of Ibuprofen can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.
    The metabolism of 9-aminocamptothecin can be decreased when combined with Ibuprofen.
    Ibuprofen may decrease the excretion rate of Abacavir which could result in a higher serum level.
    The metabolism of Ibuprofen can be increased when combined with Abatacept.
    The risk or severity of bleeding can be increased when Ibuprofen is combined with Abciximab.
    The risk or severity of hypertension can be increased when Ibuprofen is combined with Abediterol.

    References

    • 1 . Zawada ET Jr: Renal consequences of nonsteroidal antiinflammatory drugs. Postgrad Med. 1982 May;71(5):223-30. [PubMed: 7041104]
    • 2 . Townsend KP, Pratico D: Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 2005 Oct;19(12):1592-601. [PubMed: 16195368]
    • 3 . Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol. 2005 Dec;58(6):963-7. [PubMed: 16240369]
    • 4 . Geisslinger G, Dietzel K, Bezler H, Nuernberg B, Brune K: Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Toxicol. 1989 Jul;27(7):324-8. [PubMed: 2777420]
    • 5 . Bergner T, Przybilla B: Photosensitization caused by ibuprofen. J Am Acad Dermatol. 1992 Jan;26(1):114-6. [PubMed: 1531054]
    • 6 . Dill J, Patel AR, Yang XL, Bachoo R, Powell CM, Li S: A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J Neurosci. 2010 Jan 20;30(3):963-72. doi: 10.1523/JNEUROSCI.5045-09.2010. [PubMed: 20089905]
    • 7 . Adams SS: The propionic acids: a personal perspective. J Clin Pharmacol. 1992 Apr;32(4):317-23. [PubMed: 1569234]
    • 8 . Rainsford KD: Discovery, mechanisms of action and safety of ibuprofen. Int J Clin Pract Suppl. 2003 Apr;(135):3-8. [PubMed: 12723739]
    • 9 . Halford GM, Lordkipanidze M, Watson SP: 50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams. Platelets. 2012;23(6):415-22. doi: 10.3109/09537104.2011.632032. Epub 2011 Nov 18. [PubMed: 22098129]
    • 10 . Bushra R, Aslam N: An overview of clinical pharmacology of Ibuprofen. Oman Med J. 2010 Jul;25(3):155-1661. doi: 10.5001/omj.2010.49. [PubMed: 22043330]
    • 11 . Adams SS, McCullough KF, Nicholson JS: The pharmacological properties of ibuprofen, an anti-inflammatory, analgesic and antipyretic agent. Arch Int Pharmacodyn Ther. 1969 Mar;178(1):115-29. [PubMed: 5353466]
    • 12 . Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM: Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J Pharm Sci. 2005 Oct;94(10):2121-31. doi: 10.1002/jps.20444. [PubMed: 16136567]
    • 13 . Sharma PK, Garg SK, Narang A: Pharmacokinetics of oral ibuprofen in premature infants. J Clin Pharmacol. 2003 Sep;43(9):968-73. [PubMed: 12971028]
    • 14 . Tan SC, Patel BK, Jackson SH, Swift CG, Hutt AJ: Ibuprofen stereochemistry: double-the-trouble? Enantiomer. 1999;4(3-4):195-203. [PubMed: 10550887]
    • 15 . Konstan MW, Krenicky JE, Finney MR, Kirchner HL, Hilliard KA, Hilliard JB, Davis PB, Hoppel CL: Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther. 2003 Sep;306(3):1086-91. doi: 10.1124/jpet.103.052449. Epub 2003 Jun 13. [PubMed: 12807998]
    • 16 . Moore PA, Hersh EV: Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6. [PubMed: 11315375]
    • 17 . Dawood MY: Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006 Aug;108(2):428-41. doi: 10.1097/01.AOG.0000230214.26638.0c. [PubMed: 16880317]
    • 18 . Krishna S, Pukrittayakamee S, Supanaranond W, ter Kuile F, Ruprah M, Sura T, White NJ: Fever in uncomplicated Plasmodium falciparum malaria: randomized double-'blind' comparison of ibuprofen and paracetamol treatment. Trans R Soc Trop Med Hyg. 1995 Sep-Oct;89(5):507-9. [PubMed: 8560525]
    • 19 . Evers S, Rahmann A, Kraemer C, Kurlemann G, Debus O, Husstedt IW, Frese A: Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology. 2006 Aug 8;67(3):497-9. doi: 10.1212/01.wnl.0000231138.18629.d5. Epub 2006 Jun 14. [PubMed: 16775229]
    • 20 . Casper D, Yaparpalvi U, Rempel N, Werner P: Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett. 2000 Aug 11;289(3):201-4. [PubMed: 10961664]
    • 21 . Ton TG, Heckbert SR, Longstreth WT Jr, Rossing MA, Kukull WA, Franklin GM, Swanson PD, Smith-Weller T, Checkoway H: Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord. 2006 Jul;21(7):964-9. doi: 10.1002/mds.20856. [PubMed: 16550541]
    • 22 . Harris RE, Kasbari S, Farrar WB: Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999 Jan-Feb;6(1):71-3. [PubMed: 9864404]
    • 23 . Rainsford KD: Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009 Dec;17(6):275-342. doi: 10.1007/s10787-009-0016-x. Epub 2009 Nov 21. [PubMed: 19949916]
    • 24 . Tracy TS, Hall SD: Metabolic inversion of (R)-ibuprofen. Epimerization and hydrolysis of ibuprofenyl-coenzyme A. Drug Metab Dispos. 1992 Mar-Apr;20(2):322-7. [PubMed: 1352228]
    • 25 . Rao P, Knaus EE: Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008 Sep 20;11(2):81s-110s. [PubMed: 19203472]
    • 26 . Hall AH, Smolinske SC, Conrad FL, Wruk KM, Kulig KW, Dwelle TL, Rumack BH: Ibuprofen overdose: 126 cases. Ann Emerg Med. 1986 Nov;15(11):1308-13. [PubMed: 3777588]
    • 27 . Current issues in pharmacy and medical sciences [Link]

    Recent Questions